130 related articles for article (PubMed ID: 31731087)
21. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum.
Dubey D; David WS; Reynolds KL; Chute DF; Clement NF; Cohen JV; Lawrence DP; Mooradian MJ; Sullivan RJ; Guidon AC
Ann Neurol; 2020 May; 87(5):659-669. PubMed ID: 32086972
[TBL] [Abstract][Full Text] [Related]
22. [Neurotoxicity and dermatologic toxicity of cancer chemotherapy].
Nakane M
Gan To Kagaku Ryoho; 2006 Jan; 33(1):29-33. PubMed ID: 16410694
[TBL] [Abstract][Full Text] [Related]
23. CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.
McGinnis GJ; Raber J
Immunotherapy; 2017 Sep; 9(11):929-941. PubMed ID: 29338610
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity?
Cavaletti G; Alberti P; Marmiroli P
Am Soc Clin Oncol Educ Book; 2015; ():e553-60. PubMed ID: 25993222
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy-Related Neurotoxicity.
Taillibert S; Le Rhun E; Chamberlain MC
Curr Neurol Neurosci Rep; 2016 Sep; 16(9):81. PubMed ID: 27443648
[TBL] [Abstract][Full Text] [Related]
26. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis.
Guzman-Prado Y; Ben Shimol J; Samson O
Cancer Immunol Immunother; 2021 Jan; 70(1):89-100. PubMed ID: 32648164
[TBL] [Abstract][Full Text] [Related]
27. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
Daxini A; Cronin K; Sreih AG
Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
[TBL] [Abstract][Full Text] [Related]
28. Anti-PD1/PDL1 induced psoriasis.
Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
[TBL] [Abstract][Full Text] [Related]
29. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules.
Caraglia M; Santini D; Bronte G; Rizzo S; Sortino G; Rini GB; Di Fede G; Russo A
Curr Drug Metab; 2011 Dec; 12(10):944-55. PubMed ID: 21787268
[TBL] [Abstract][Full Text] [Related]
30. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
31. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
[TBL] [Abstract][Full Text] [Related]
32. Techniques for the neurological examination of taxane-induced neuropathy.
Ohsumi S; Sunada Y
Breast Cancer; 2004; 11(1):86-91. PubMed ID: 14718799
[TBL] [Abstract][Full Text] [Related]
33. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
Simonsen AB; Kaae J; Ellebaek E; Svane IM; Zachariae C
J Am Acad Dermatol; 2020 Nov; 83(5):1415-1424. PubMed ID: 32320766
[TBL] [Abstract][Full Text] [Related]
35. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
[TBL] [Abstract][Full Text] [Related]
36. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Wang JX; Wu HL; Zhu M; Zhou R
Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
[TBL] [Abstract][Full Text] [Related]
37. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.
Hershman DL; Till C; Wright JD; Awad D; Ramsey SD; Barlow WE; Minasian LM; Unger J
J Clin Oncol; 2016 Sep; 34(25):3014-22. PubMed ID: 27325863
[TBL] [Abstract][Full Text] [Related]
38. Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity.
Cavaletti G; Ceresa C; Nicolini G; Marmiroli P
Anticancer Res; 2014 Jan; 34(1):483-6. PubMed ID: 24403505
[TBL] [Abstract][Full Text] [Related]
39. Neurotoxicity and Immunotherapy.
Kopecký J
Klin Onkol; 2020; 33(1):11-14. PubMed ID: 32075382
[TBL] [Abstract][Full Text] [Related]
40. Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.
Sands S; Ladas EJ; Kelly KM; Weiner M; Lin M; Ndao DH; Dave A; Vahdat LT; Bender JG
Support Care Cancer; 2017 Mar; 25(3):701-708. PubMed ID: 27830395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
